Type 1 Diabetes Mellitus Clinical Trial
Official title:
Prevention of Hypoglycemia After Exercise Using DreaMed Substance Administration Device in Children and Adolescents With Type 1 Diabetes (The PHYSI-DREAM Study)
The Study will compare treatment with Closed Loop (CL) system - DreaMed MD-AID to the
standard treatment without computer algorithm decisions - SAP therapy in 20 children and
adolescents with Type 1 Diabetes (T1D) during and after afternoon physical activity.
The aims of the study are:
- to demonstrate that the use of DreaMed MD-AID is safe during physical activity
- to investigate the risk of hypoglycemia among children and adolescents with T1D after
afternoon exercise during closed-loop control.
This is investigator initiated, single-center, open-label, crossover, randomized,
interventional, in-hospital pediatric study, performed at the University Children's Hospital,
University Medical Center Ljubljana.
Study duration will be about 4 weeks per subject, 6 month overall. The study will compare
Continuous Glucose Monitoring (CGM) based time in hypoglycemia in an intervention arm
(Glucose control using DreaMed MD-AID) to a control arm (Glucose control using SAP).
Each arm includes two exercise days with 1 week in-between. Subjects will be randomly
assigned to participate first in the intervention arm (10 subjects) or first in the control
arm (10 subjects). At the end of the first period patients will be asked to participate in
another, i.e. the other arm with at least one week between arms.
Subjects will be instructed to consume a similar diet and avoid caffeine, alcohol, and
physical activity in the 48 hours before the exercise day visit.
The start of the run-in period can be scheduled as a separate visit, but not more than 2 days
after screening.
All subjects will attend the clinic on six occasions:
- Visit 1: Screening and sensor/pump education, detailed physical examination will be
performed, all subject will have to meet inclusion/exclusion criteria.
- Visit 2: Baseline assessment of the DreaMed MD-AID profile, subjects will perform
resting electrocardiography (ECG) and determination of the maximal oxygen consumption
rate (VO2max) on a cycle ergometer Ganshorn LF8.5G™ and Schiller software, with BG
measurements before, at the end of the exercise and 2 hours after exercise. Subjects
will be instructed to refrain from physical activity for 48 hours prior to visits 3 - 6.
- Visit 3: 24 hours DreaMed MD-AID or SAP with afternoon exercise (in the time between
16:30 and 19:30): an i.v. catheter will be inserted in the antecubital or cephalic vein
(for plasma BG and emergency). Cycle ergometer will be adjusted for each subject (work
rate, seat height,..), they will be instructed to pedal at steady rate of 50-60
rotations per minute (RPM).The subjects will cycle for 40 minutes at 55% Vo2max load
(starting work rate set to 30 watts (W) with linear loading to reach 55% VO2max on 5:00
minute exercise time) - the aim of this session is to induce delayed hypoglycemia.
- Visit 4: 24 hours DreaMed MD-AID or SAP with afternoon exercise (in the time between
16:30 and 19:30): an i.v. catheter will be inserted in the antecubital or cephalic vein
(for plasma BG and emergency). Cycle ergometer will be adjusted for each subject (work
rate, seat height,..), they will be instructed to pedal at steady rate of 50-60
rotations per minute (RPM). The subjects will cycle for 40minutes - high intensity
interval training (2 - 6 sprints of 20 seconds at 80% VO2max with interval of 6 minutes
low-moderate activity (55% VO2max (total of ~40 minutes) between the sprint. The aim of
this session is to imitate children's physical activity (bursts of intensive physical
activity interspersed with varying intervals of activity of low and moderate intensity.
- Visit 5&6: Same as visits 3 and 4, cross over from DreaMed MD-AID to SAP or vice versa.
During the exercise, a continuous ECG will be recorded and inhaled O2 and exhaled Carbon
Dioxide (CO2) will be measured.
BG and lactate will be taken during the exercise visits: at the beginning of the exercise,
after every 15 min exercise session, and every half an hour for the next 2 hours thereafter.
All hypoglycemia will be confirmed with SBGM: glucose values <3.3 (60 mg/dl) mmol/l if
symptomatic, and all hypoglycemia with self blood glucose monitoring (SBGM) values <2.8
mmol/l (50 mg/dl) (regardless of symptoms) will be treated with rescue carbohydrates as per
standard in-hospital procedure (15 g sugar per 10 kg of body weight (BW), re-evaluate and
repeat if necessary in 15-30 minutes).
New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the
subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.
Schedule for all exercise days will be similar:
- 12:00 hospital admission
- 13:00 lunch
- 13:30 to 16:00 rest
- 16:00 afternoon snack
- 16:30 to 19:30 exercise protocol
- 19:45 dinner
- 21:00 to 7:30 next day: bed time
- 8:00 breakfast.
- 13:00 lunch and end of study
Subjects will have standardized and similar meals on all exercise days (lunch at 13:00,
afternoon snack at 16:00, dinner at 19:45, and breakfast at 8:00 the next day), based on the
weight, with calculated carbohydrates and calories: 1 gram of carbohydrates per kilogram, the
content of the meal according to the recommendation: comprising of 50% carbohydrate, 20%
protein, and 30% fat, of which no more than 10% will be saturated fat. During the exercise
the SAP group will turn off the insulin pump and lower their basal insulin for 20% for the
next 4 hours after the exercise.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04476472 -
Omnipod Horizon™ Automated Glucose Control System Preschool Cohort
|
N/A | |
Completed |
NCT03635437 -
Evaluation of Safety and Diabetes Status Upon Oral Treatment With GABA in Patients With Longstanding Type-1 Diabetes
|
Phase 1/Phase 2 | |
Completed |
NCT04909580 -
Decision Coaching for Youth and Parents Considering Insulin Delivery Methods for Type 1 Diabetes
|
N/A | |
Active, not recruiting |
NCT00679042 -
Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol
|
Phase 3 | |
Completed |
NCT03293082 -
Preschool CGM Use and Glucose Variability in Type 1 Diabetes
|
N/A | |
Completed |
NCT04016662 -
Automated Insulin Delivery in Elderly With Type 1 Diabetes (AIDE T1D)
|
Phase 4 | |
Completed |
NCT02527265 -
Afrezza Safety and Pharmacokinetics Study in Pediatric Patients
|
Phase 2 | |
Completed |
NCT03738865 -
G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes
|
Phase 3 | |
Completed |
NCT03240432 -
Wireless Innovation for Seniors With Diabetes Mellitus
|
N/A | |
Completed |
NCT03168867 -
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
|
N/A | |
Completed |
NCT03674281 -
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
|
N/A | |
Completed |
NCT03669770 -
Ultrasound Classification and Grading of Lipohypertrophy and Its Impact on Glucose Variability in Type 1 Diabetes
|
||
Recruiting |
NCT03682640 -
Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes
|
Phase 2 | |
Recruiting |
NCT04096794 -
Chinese Alliance for Type 1 Diabetes Multi-center Collaborative Research
|
||
Completed |
NCT02882737 -
The Impact of Subcutaneous Glucagon Before, During and After Exercise a Study in Patients With Type 1 Diabetes Mellitus
|
N/A | |
Recruiting |
NCT02745808 -
Injectable Collagen Scaffold™ Combined With HUC-MSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Withdrawn |
NCT02518022 -
How to be Safe With Alcoholic Drinks in Diabetes
|
N/A | |
Completed |
NCT02558491 -
Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM
|
N/A | |
Withdrawn |
NCT02579148 -
Collagen Scaffolds Loaded With HUCMSCs for the Improvement of Erectile Function in Men With Diabetes
|
Phase 1 | |
Completed |
NCT02562313 -
A Trial Investigating the Continuous Subcutaneous Insulin Infusion of a Liquid Formulation of BioChaperone Insulin Lispro in Comparison to Humalog®
|
Phase 1 |